Oral Presentation Australasian Society for Immunology Annual Scientific Meeting 2014

The HLDA10 workshop wet laboratory studies (#147)

Georgina J Clark 1 , Pablo A Silveira 2 , Phillip D Fromm 2 , Leticia Muusers 2 , Fiona Kupresanin 2 , Xinsheng Ju 2 , Zehra Elgundi 2 , Robin Gasiorowski 2 , Michael S Papadimitrious 2 , Kevin Lo 2 , Christian Bryant 2 , Nirupama D Verma 2 , Ghaith Bakdash 3 , Kifah Shahin 2 , Zamil Mattar 2 , Elizabeth Newman 4 , Kenneth F Bradstock 5 , Derek NJ Hart 1
  1. University of Sydney, Sydney, N/A, Australia
  2. ANZAC Research Institute , Sydney, N/A, Australia
  3. Department of Tumor Immunology, Raboud Institute for Molecular Life Sciences, Nijmegen, Netherlands
  4. Concord Repatriation General Hospital, Sydney, NSW, Australia
  5. Westmead Hospital, Westmead, NSW, Australia

HLDA10 is the tenth Human Leucocyte Differentiation Antigen (HLDA) Workshop. The introduction of monoclonal antibodies (mAbs) provided the scientific community with many reagents that revolutionised the type of questions scientists could address both in vitro and in vivo. They have become essential for defining cell populations and are used routinely in an increasing number of technologies. Ongoing advances in conjugates and machine technology continues to enhance their utility. Clinically, mAbs are the leading class of therapeutics in terms of market share. Most immunological laboratories rely on mAbs with defined specificity for their readouts. This reliance on their defined specificities makes the validation of mAb to be of the utmost importance. Standardisation and validation of mAbs is crucial if research knowledge is to be shared and used to translate laboratory findings into clinical therapies. The HLDA Workshops provide a mechanism to engage via inter and intra laboratory collaboration to do this.

The Workshop has followed the format of earlier ones. As the host laboratory, we invited researchers from national and international academic and commercial institutions to submit mAbs to human leucocyte surface membrane molecules, particularly those that recognised molecules to human myeloid and dendritic cell (DC) populations. These antibodies were tested initially for activity and distributed to 15 international laboratories that tested the panel on different leucocyte populations. The populations tested included: blood DC populations, tonsil leucocytes, monocyte derived DC, CD34 derived DC, macrophage subpopulations, and diagnostic lymphoma and acute myeloid leukaemic samples. Each laboratory was provided with enough mAb to perform 5 repeat experiments. Submitted mAbs to some molecules were further validated to collate data required to designate a formal CD number. This collaborative process provides the broader scientific community with an invaluable database on the reagents that they use in research, and target for therapeutic products.